The effects of combinations of antifungal and antineoplastic drugs on inhibition of the growth of yeasts which commonly infect cancer patients have been analyzed. It was shown that (i) inhibitory drug combinations could be selected in which all drugs were at levels far below their individual MICs; (ii) interactive effects among antineoplastic and antifungal drugs may be very large; (iii) optimum combinations of drugs for inhibition of yeast growth depended upon both the relative and absolute concentrations of the drugs in the mixture; (iv) drug combinations which were effective at low levels in inhibiting one test yeast were also generally effective against other species, but the levels of susceptibilities and, to a lesser extent, the best ratios of drugs in the test combinations varied with species; and (v) to quantitatively evaluate drug interactions, it is necessary to carefully define and control all experimental conditions, absolute and relative concentrations of drugs used, and the organisms tested.
Immunosuppressed patients receiving antineoplastic chemotherapy are specifically susceptible to opportunistic infections (6) . Treatment of microbial infections requires either a discontinuation of cancer chemotherapy or the use of drugs in combinations which can simultaneously treat both the neoplasm and the infection. Selection of drugs for combined treatments has been difficult because of interactive effects among test drugs which may enhance or inhibit the action of each drug alone. Moreover, antimicrobial drugs, and particularly antifungal agents, may have severe toxic side effects on the host (2) . New regimens for combined drug treatment must be developed to maximize their effectiveness.
A major goal of studies of combined-drug therapy for fungus-infected cancer patients is to define mixtures of drugs which mutually potentiate inhibitory effects on fungal growth so that minimal levels of the toxic drugs may be used. This must include not only studies with mixtures of antifungal drugs but also evaluations of the antifungal effects of the antineoplastic drugs and of combinations of antifungal plus antineoplastic agents. Selection of the best regimens for combined-drug treatment must rely upon understanding interactive effects among the antifungal and antineoplastic drugs. The number of possible combinations of drugs which should be evaluated for treatments thus becomes very large.
There are numerous reports of studies of the effects of combined antifungal agents on the inhibition of Candida species (7, 9) . Many of these studies offer encouraging evidence that combined-drug treatments can synergistically affect fungal growth, although the methods used in such studies fall short of allowing predictions of optimum conditions for inhibition. Little work has been done to define optimum conditions for combined antineoplastic and antifungal drugs in inhibiting fungal growth.
The most frequently isolated yeast species in cancer patients are Candida albicans, C. tropicalis, C. glabrata, C. parapsilosis, and C. krusei. These accounted for 97.1% of the isolates obtained from cancer patients in a study by * Corresponding author. Kiehn et al. (5) at Memorial Sloan-Kettering Cancer Center. C. albicans and C. tropicalis accounted for 97.2% of all yeast species isolated from cancer patients treated at Kuwait Cancer Control Center (4). In addition, 12 other species have been less frequently isolated (5) .
In this study, we report the results of multifactorial studies of combinations of antifungal and antineoplastic drugs used to inhibit the growth of seven yeast species, which include species primarily responsible for infections of cancer patients (5). The primary and interactive effects among these drugs are quantified, and drug concentrations which are highly effective in inhibiting fungal growth in vitro are defined. Effective inhibition was obtained in some trials at drug levels far below the MICs of individual drugs, suggesting combinations that may be selected for their minimal toxic side effects in treatment of infected patients.
MATERIALS AND METHODS
Organisms. Seven species of yeasts were studied: C. albicans KCCC 14172, C. tropicalis KCCC 13622, C. parapsilosis KCCC 14275, C. krusei KCCC 15312, C. kefyr KCCC 13709, C. glabrata KCCC 14801, and Trichosporon cutaneum KCCC 15286. These yeasts were oral isolates obtained from patients undergoing therapy at the Kuwait Cancer Control Center, except T. cutaneum, which was a blood isolate. Methods of isolation and identification of these species were as described previously (4 
RESULTS
Combinations of three antitumor drugs, 5-FU, MT, and CP, and of three antifungal drugs, AB, MN, and FC, were tested for their abilities to inhibit the growth of seven species of yeasts (Table 1) . To test a wide range of concentrations and ratios of drug concentrations in a manageably small number of experiments, we used a 23 factorial design for simultaneously varying concentrations of each of the antifungal or antineoplastic drugs. The drug levels used as the initial concentrations for each experimental point are shown in Table 1 . High levels of the drugs (MIC levels) were coded as +, low levels were coded as -, and medium levels were coded as 0. The actual drug concentrations corresponding to these coded values are presented in Table 1 , footnote a. Values representing the maximum dilution of each test drug combination which caused zero visible growth of the various yeasts are also shown in Table 1 . The actual concentrations of each drug in these mixtures at the lowest levels causing inhibition can be obtained by dividing the appropriate + orconcentration by 2', where n is the value of the endpoint dilutions (Table 1) . For example, inhibitory concentrations in trial 1A for C. krusei by antineoplastic drugs were as follows: 5-FU, (78/23) = 9.75 ,ug/ml; MT, 400/23 = 50 ,ug/ml; and CP, 250/23 = 36.25 ,ug/ml.
Susceptibilities of the organisms to the test combinations differed widely. C. glabrata and C. kefyr were both very susceptible to inhibition by the antineoplastic drugs as well as the antifungal drugs, whereas the species of T. cutaneum, C. krusei, C. tropicalis, C. parapsilosis, and C. albicans were generally more resistant. Yeast susceptibilities to the drugs varied with the particular drug combination used, and each individual species tested showed a unique pattern of inhibition dependent upon the absolute as well as the relative concentrations of the three drugs (Table 1) .
Qualitative indications of drug interactions are immediately apparent from the data in Table 1 . If there were no positive or negative interactions between drugs, the combination in which all were initially at their highest concentrations (i.e., +, +, +) should be inhibitory at the highest dilution. Clearly, this is not uniformly the case. Furthermore, if all the yeasts responded similarly to the drug combinations, the pattern of the particular mixtures of drugs that are more or are less effective would be expected to be the same for all species tested. This was not observed. When antineoplastic drugs are used, the mixture (+, -, -) (i.e., an initial mixture high in 5-FU but low in MT and CP) was most effective in the inhibition of several of the species, but different drug combinations worked as well if not better for other species. Although each of the seven test species responded differently to changes in the drug mixtures, a consistent trend was noted among all species, which allowed a definition of better or poorer combinations for inhibition. This is reflected by the averages listed in Table 1 . Thus, it is possible to select particular ratios of drugs in combinations which have generally high levels of toxicity to all species tested.
Using the endpoint determination data in Table 1 , we wrote general linear regression equations to describe the inhibition results quantitatively. These equations are presented in two forms in Table 2 for each organism tested. The first fits concentrations in coded form (-1 to +1), and the second is converted for use with actual drug concentrations. The value of y is the number of twofold dilutions which can be made for a test mixture while still obtaining zero visible growth. The magnitudes of the coefficients CO to C7 in the regression equations indicate the magnitudes of primary and interactive effects among the drugs. The sign of each coefficient indicates whether the term has a beneficial (+) or a negative (-) effect on inhibition. For example, from the negative signs of the coefficients C2 in Table 2 , it is evident that the primary effect of increasing the levels of MT antifungal plus two antineoplastic agents were used are presented in Table 3 . In this experiment we used a two-level factorial design with high (+), low (-), and mid-level (0) concentrations in cornbinations as shown in the table. The +, -, and 0 levels here are the same as shown in Table 1 . A fit of the data to a quadratic model was also tested by using a three-level Box-Behnken design; the linear polynomial model, which required fewer tests, provided a somewhat better fit of the data over the concentration ranges studied (3) . Sixteen drug combinations were tested, again in a fully randomized and replicated fashion. Strong interactions were noted between antineoplastic drugs, between antifungal drugs, and among the combinations of antineoplastic plus antifungal drugs. Considering all the trial points, the combination of drugs which is most generally effective for all the species (i.e., lowest drug concentrations which were inhibitory) was combination no. 6 (Table 3) . In this mixture, initial concentrations were coded (+, -, +, -), i.e., high levels of MN and 5-FU, with low levels of AB and MT. This combination at a dilution of 25 completely inhibited all the test strains; at 26 it inhibited five of seven. The actual concentrations of drugs at each of these inhibitory levels are readily determined by inserting concentrations corresponding to the coded values and calculating dilutions. For example, the (-) level of AB is 0.015 ,ug/ml. The concentration of AB in solutions which inhibit the growth of five of seven test organisms is 0.015/26 = 2.3 x 10-4 ,ug/ml; for MN, 5-FU, and MT, the concentrations are 0.061, 28, and 3.9 jig/ml, respectively.
Data from the test points in Table 3 were analyzed to produce polynomial equations which adequately fit the data and hence allow predictions of inhibitory levels of various combinations of these drugs which have not been experi- Table 4 for each test organism. Table 5 summarizes the effects of changes in assay conditions on the apparent inhibitory levels of drug combinations. Major effects are noted with changes in medium, assay temperature, and inoculum size. Not all species were affected equally by these parameters. Note that C. krusei is insensitive to the medium change and C. tropicalis is not significantly affected by incubation temperature differences.
DISCUSSION
There has been considerable discussion in the literature regarding methods for measuring drug inhibition of fungal C0 C1  C2  C3  C4  C5  C6  C7  C8  C9   CIO   C11   C12  C13  C14  R2 C. Inhibition levels have been cited as concentrations of drugs which reduce growth to zero or to some defined percentage of that of controls. A major problem has been the wide concentration range of some drugs giving only partial inhibition. This has led to uncertainties, particularly in drug combination studies (8) . Several careful analyses have been made, employing more than one criterion for inhibition or monitoring growth over the entire time of contact between drugs and cells, to reduce the uncertainties (9) .
The goal of this project was to find drug combinations which could, at low concentrations, completely inhibit yeast growth. Accordingly, a drug mixture was scored as inhibitory in these studies only at levels at which zero growth was observable. Decreased growth rates and partial inhibition were not considered. Complete inhibition of growth seems a proper scoring criterion in seeking drug combinations which may be able to block yeast infections or clear up existing infections in host organisms. This scoring method offers several advantages experimentally. For example, it is not necessary to make repeated measurements of growth versus time or to integrate dose-time effects.
Our studies with either three antineoplastic drugs or three antifungal drugs showed that each yeast species responded somewhat differently to the varied drug combinations, but that there was a general consistency among responses. A combination which was effective in inhibiting the growth of one yeast species at low concentrations was generally one of the better combinations for effective inhibition of the other species. This study has shown that it is possible to readily select drug combinations which are toxic to yeast strains at levels far below the MICs of any individual drugs in the combination.
To make this selection, we developed polynomial equations. Polynomial expressions for each organism can be solved, subject to any imposed constraints, to select the best mixture of drugs for growth inhibition. For example, if a constraint is imposed that the AB concentration in the mixture is not to exceed 0.002 ,ug/ml, one could select the best mix of the other three drugs to kill the test orgapism. A practical application might be to set 5-FU and MT at levels commonly used clinically in animal chemotherapy and use the equations in Table 4 to find minimal levels of AB or MN which would block growth in the presence of these clinical levels of the antineoplastic drugs. Selection of the best mixture of drugs for inhibiting yeast growth depends critically upon the definition of best. One definition with some possible clinical relevance might be to have the total drug levels as low as possible to avoid toxic side effects. Another might be to aim at minimizing levels of one particular drug. Still a third might be to fix one or more drugs, e.g., the antineoplastic drugs, at a clinical level and select minimal effective levels of the antifungal agents (as a prophylactic antifungal treatment). A fourth definition might be to select drug combinations that have a wide spectrum of activity for prophylactic treatments, i.e., to select a drug combination which can inhibit a high percentage of possible infective yeasts. The best drug combinations for each of these scenarios can be determined by solution of the polynomial equations with appropriately defined limitations on the term best.
Although it has long been known that drug synergism is possible, the critical dependence of synergistic effects not only upon the drugs selected but also upon their concentration ratios has not previously been emphasized. Obtaining such conclusions became possible only when multifactorial analysis studies were used. It is evident that future experiments aimed at optimum combination drug therapy must simultaneously treat both absolute and relative concentrations of drugs. It would also appear that three-and four-drug combinations may in some cases prove far superior to two-drug combinations. It is evident that simple statements (such as drug A is synergistic with drug B) are no longer acceptable. Test conditions, absolute and relative concentrations, and organisms tested must be clearly defined.
